Antifungal susceptibility of Cryptococcus neoformans and Cryptococcus gattii isolates from decayed wood of trunk hollows of Ficus religiosa and Syzygium cumini trees in north-western India

被引:31
作者
Khan, Zia U. [1 ]
Randhawa, Harbans S.
Kowshik, Tusharantak
Chowdhary, Anuradha
Chandy, Rachel
机构
[1] Kuwait Univ, Fac Med, Dept Microbiol, Mycol Reference Lab, Kuwait, Kuwait
[2] Univ Delhi, Vallabhbhai Patel Chest Inst, Dept Med Mycol, Delhi 110007, India
关键词
Etest; fluconazole; itraconazole; voriconazole; amphotericin B;
D O I
10.1093/jac/dkm192
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: We present antifungal susceptibility data on environmental isolates of Cryptococcus neoformans (serotype A, n = 117) and Cryptococcus gattii (serotype B, n = 65) cultured from decayed wood of trunk hollows of Ficus religiosa and Syzygium cumini trees. Methods: Susceptibilities to amphotericin B, fluconazole, ketoconazole, itraconazole and voriconazole were determined by using Etest. The MICs were read after 48 h as per the guidelines provided by the manufacturer. Results: The MIC(90)s and susceptibility ranges for C. neoformans isolates were as follows: 0.094 (0.004-0.25) mg/L for amphotericin B, 4 (0.032-12) mg/L for fluconazole, 0.094 (0.004-0.75) mg/L for itraconazole, 0.064 (0.002-0.19) mg/L for ketoconazole, and 0.047 (0.006-0.125) mg/L for voriconazole, whereas for C. gattii isolates these were 0.125 (0.023-0.5) mg/L for amphotericin B, 8 (0.032-16) mg/L for fluconazole, 0.75 (0.006-2) mg/L for itraconazole, 0.125 (0.003-0.19) mg/L for ketoconazole, and 0.094 (0.004-0.125) mg/L for voriconazole. A comparison of the geometric means of MICs (mg/L) revealed that C. gattii was less susceptible than C. neoformans to amphotericin B (0.075 versus 0.051 9 P = 0.0003), fluconazole (2.9,12 versus 2.316, P = 0.003), itraconazole (0.198 versus 0.0344, P < 0.0001), ketoconazole (0.072 versus 0.037, P < 0.0001), and voriconazole (0.045 versus 0.023, P < 0.0001). Conclusions: The antifungal susceptibility data obtained in this study indicate that the occurrence of primary resistance among environmental isolates of C. neoformans serotype A and C. gattii serotype B is rare, and serotype B isolates are less susceptible than serotype A isolates.
引用
收藏
页码:312 / 316
页数:5
相关论文
共 39 条
  • [1] Comparison of the Etest and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents
    Aller, AI
    Martín-Mazuelos, E
    Gutiérrez, MJ
    Bernal, S
    Chávez, N
    Recio, FJ
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (06) : 997 - 1000
  • [2] Alves Sydney Hartz, 2001, Revista do Instituto de Medicina Tropical de Sao Paulo, V43, P267, DOI 10.1590/S0036-46652001000500006
  • [3] Antifungal susceptibilities of Cryptococcus neoformans
    Archibald, LK
    Tuohy, MJ
    Wilson, DA
    Nwanyanwu, O
    Kazembe, PN
    Tansuphasawadikul, S
    Eampokalap, B
    Chaovavanich, A
    Reller, LB
    Jarvis, WR
    Hall, GS
    Procop, GW
    [J]. EMERGING INFECTIOUS DISEASES, 2004, 10 (01) : 143 - 145
  • [4] Possible development of resistance to fluconazole during suppressive therapy for AIDS-associated cryptococcal meningitis
    Armengou, A
    Porcar, C
    Mascaro, J
    GarciaBragado, F
    [J]. CLINICAL INFECTIOUS DISEASES, 1996, 23 (06) : 1337 - 1338
  • [5] The hidden danger of primary fluconazole prophylaxis for patients with AIDS
    Berg, J
    Clancy, CJ
    Nguyen, MH
    [J]. CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) : 186 - 187
  • [6] Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States:: 1992 to 1994 and 1996 to 1998
    Brandt, ME
    Pfaller, MA
    Hajjeh, RA
    Hamill, RJ
    Pappas, PG
    Reingold, AL
    Rimland, D
    Warnock, DW
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (11) : 3065 - 3069
  • [7] Antifungal susceptibilities, varieties, and electrophoretic karyotypes of clinical isolates of Cryptococcus neoformans from Brazil, Chile, and Venezuela
    Calvo, BM
    Colombo, AL
    Fischman, O
    Santiago, A
    Thompson, L
    Lazera, M
    Telles, F
    Fukushima, K
    Nishimura, K
    Tanaka, R
    Myiajy, M
    Moretti-Branchini, ML
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (06) : 2348 - 2350
  • [8] Casadevall A, 1998, CRYPTOCOCCUS NEOFORM, DOI DOI 10.1128/9781555818241
  • [9] In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia
    Chandenier, J
    Adou-Bryn, KD
    Douchet, C
    Sar, B
    Kombila, M
    Swinne, D
    Thérizol-Ferly, M
    Buisson, Y
    Richard-Lenoble, D
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2004, 23 (06) : 506 - 508
  • [10] Clinical features and in vitro susceptibilities of two varieties of Cryptococcus neoformans in Taiwan
    Chen, YC
    Chang, SC
    Shih, CC
    Hung, CC
    Luh, KT
    Pan, YS
    Hsieh, WC
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 36 (03) : 175 - 183